OCT Angiography in Wet AMD

Recruiting

• Conditions: Neovascular (Wet) Age-related Macular Degeneration (AMD)
• Interventions: Device: Optical Coherence Tomography

• Registration Number: NCT02253030
• Lead Sponsor: Oregon Health and Science University

Brief Summary

The primary goals of this study are to use optical coherence tomography (OCT) angiography (blood vessel mapping) to:

1. diagnose the presence of new blood vessels in wet age-related macular degeneration (AMD)

2. evaluate patients undergoing treatment for wet AMD

3. determine if reduced flow to the choroid is a risk factor for developing wet AMD.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2014-09
• Study First Submitted: 2014-09-25
• Study First Submitted QC: 2014-09-26
• Study First Posted: 2014-10-01
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-08
• Last Update Posted: 2024-02-12
• Primary Completion: 2026-12
• Study Completion: 2026-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 160

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Newly-diagnosed, untreated wet AMD	Optical Coherence Tomography	This group will be adults newly diagnosed with wet AMD who have not undergone any treatment for the condition. Their data will be gathered only once, prior to treatment.
Wet AMD undergoing a "treat and extend" strategy	Optical Coherence Tomography	This group will be adults with wet AMD undergoing treatment under the "treat and extend" strategy. (The "treat and extend" strategy increases the intervals between treatments as long as the macula remains dry.) They will be followed over the course of 1 year with extra imaging before extending follow-up intervals.
Wet AMD undergoing "as-needed" treatment	Optical Coherence Tomography	This group will be adults undergoing treatment as-needed for wet AMD. They will be followed monthly over the course of 1 year.
High-risk eyes	Optical Coherence Tomography	This group will be adults with wet AMD in one eye and findings of dry AMD in the other. The eye with dry AMD will be followed every 6 months for 3 years.

Primary Outcome Measures

Name	Time	Method
Measure of drusen area in mm2	3 years
Measure of CNV membrane area in mm2	1 year
Measure of choroidal neovascular (CNV) vessel area in mm2	1 year
Measure of CNV length density in mm	1 year
Measure of retinal fluid volume in mm3	1 year

Trial Locations

Locations (1)

Casey Eye Institute, Oregon Health & Science University; 🇺🇸 Portland, Oregon, United States